We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ORTEC SEEKS HDE FOR FREEZE-DRIED CELL 'SPONGE'

ORTEC SEEKS HDE FOR FREEZE-DRIED CELL 'SPONGE'

June 9, 2006

Ortec International plans to file a humanitarian device exemption (HDE) application with the FDA for another version of its previously approved product to treat disfiguring skin burns, the company said May 30. Ortec develops and commercializes regenerative and stem cell products.

The product, Orcel, fuses two types of human skin cells into separate layers with cow collagen to create a cell "sponge." The FDA approved Ortec's premarket application (PMA) for Orcel as a wound dressing for burn victims in late August 2001.

Ortec is seeking the current HDE for its cryopreserved (freeze-dried) Orcel to treat recessive dystrophic epidermmolysis bullosa (RDEB), a rare congenital skin disorder that causes painful ulcerations and scarring leading to hand and foot deformities.

Surgery performed on RDEB patients to separate fingers and toes offers patients greater mobility of their digits but requires replacement skin from another part of the patient's body. Orcel can be used directly on the wound or to cover the "donor site," an area where skin has been removed to be used for a skin graft.

HDEs are reserved for devices that treat conditions affecting fewer than 4,000 people in the U.S. This latest HDE would allow Ortec to gain approval of its frozen Orcel without having to submit additional clinical data. The company is seeking approval to market the device to patients beginning in July.

Absorbed by the body, the living human skin cells used in Orcel produce proteins that can help heal wounds and "may stimulate a patient's own skin to heal itself," the FDA explains in its description of the product.

(http://www.fdanews.com/ddl/33_23/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing